No effective disease-modifying treatments exist for progressive neurodegenerative diseases associated with aging. AbbVie sponsored and funded the study, contributed to the design, participated in the collection, analysis, and interpretation of data, and in writing, reviewing, and approval of the final publication.Ĭompeting interests: The authors have declared that no competing interests exist. All authors received salaries from AbbVie during completion of these studies, and may own AbbVie stock. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.ĭata Availability: All relevant data are within the paper and its Supporting Information files.įunding: All authors are or were employees of AbbVie, Inc. Received: SeptemAccepted: Published: June 2, 2022Ĭopyright: © 2022 Self et al. PLoS ONE 17(6):Įditor: Kensaku Kasuga, Niigata University, JAPAN
Citation: Self W, Awwad K, Savaryn JP, Schulz M (2022) An immuno-enrichment free, validated quantification of tau protein in human CSF by LC-MS/MS.
